Reozalimab

• CAT Number: I040850
• CAS Number: 2445259-99-2
• Purity: ≥95%

Reozalimab (Cat No.: I040850) is a humanized monoclonal antibody targeting complement component C5, developed to inhibit terminal complement activation. By blocking C5 cleavage, Reozalimab prevents the formation of pro-inflammatory C5a and membrane attack complex (MAC), offering therapeutic potential in complement-mediated disorders such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Its mechanism enables investigation into complement dysregulation and immune-mediated tissue damage. Reozalimab supports studies in immunology and hematology. For research use only in laboratory and preclinical applications.

Reference

[1]. Pattabiraman, et al. Synthetic IL-7 and IL-7-anti-PD-1 antibody immunocytokines for cancer therapy. World Intellectual Property Organization, WO2023281484 A1 2023-01-12.

[2]. Reozalimab. IMGT/mAb-DB.